Omada Health Inc. Common Stock (OMDA)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits and sell at a sensible price. Omada Health is not there yet. It sells virtual care programs for cardiometabolic conditions, musculoskeletal therapy, weight management, and behavioral health. Revenue is growing: in fiscal 2025, the year ended 2025-12-31, revenue was $260.2M, up from $169.8M in fiscal 2024 and $122.8M in fiscal 2023. Yet it lost $12.8M in fiscal 2025, $47.1M in fiscal 2024, and $67.5M in fiscal 2023. The latest quarter is encouraging: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $87.8M, net income was $5.3M, and diluted EPS was $0.08. That is a real turn, but one quarter does not make a durable moat. The business may have some stickiness with health plans and employers, but virtual care is competitive and reimbursement can change. Financial returns are still weak: ROE is 1.84%, ROCE is -0.09%, and trailing free cash flow is $17.1M, a 1.5% FCF yield. At the 2026-10-13 close of $18.30, the FairStock P/E is 76.25, P/B is 4.39, EV/EBITDA is 84.79, and Graham Number is $4.75, implying a -285.26% margin of safety. The FairStock Score is 34/100, and the Lynch category is none because it lost money each of the last three years. Growth is promising, but the price already assumes a lot. I would need more quarters of profit and a wider discount before calling it a value investment.

In plain English: Omada Health sells virtual health programs for conditions like diabetes, high blood pressure, physical therapy, weight loss, and behavioral health. Revenue is growing quickly and the latest quarter showed a small profit, but the company lost money in each of the last three full years. At $18.30, the stock looks expensive compared with those profits and its accounting value, so it would need continued fast growth to justify the price.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer